Brain perfusion imaging under acetazolamide challenge for detection of impaired cerebrovascular reserve capacity: positive findings with O-15-water PET in patients with negative Tc-99m-HMPAO SPECT
Standard
Brain perfusion imaging under acetazolamide challenge for detection of impaired cerebrovascular reserve capacity: positive findings with O-15-water PET in patients with negative Tc-99m-HMPAO SPECT. / Acker, Güliz; Lange, Catharina; Schatka, Imke; Pfeifer, Andreas; Czabanka, Marcus A; Vajkoczy, Peter; Buchert, Ralph.
In: J NUCL MED, Vol. 59, No. 2, 02.2018, p. 294-298.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Brain perfusion imaging under acetazolamide challenge for detection of impaired cerebrovascular reserve capacity: positive findings with O-15-water PET in patients with negative Tc-99m-HMPAO SPECT
AU - Acker, Güliz
AU - Lange, Catharina
AU - Schatka, Imke
AU - Pfeifer, Andreas
AU - Czabanka, Marcus A
AU - Vajkoczy, Peter
AU - Buchert, Ralph
N1 - Copyright © 2017 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PY - 2018/2
Y1 - 2018/2
N2 - Cerebrovascular reserve capacity (CVRC) is an important parameter for treatment decisions in chronic cerebrovascular diseases. It can be assessed by measuring the acetazolamide-induced change in regional cerebral blood flow using SPECT with 99mTc-labeled hexamethylpropyleneamine oxime (99mTc-HMPAO) or PET with 15O-water. Methods: Our database was searched for patients with moyamoya vasculopathy or atherosclerotic cerebrovascular disease who had undergone 15O-water PET after normal 99mTc-HMPAO SPECT results with respect to CVRC. 15O-water PET was analyzed visually and quantitatively. Quantitative analysis was based on parametric CVRC maps generated by voxelwise image subtraction. Results: The search identified 18 patients (43 ± 15 y, 12 moyamoya vasculopathy). PET revealed impaired CVRC in 8 patients (44%). Quantitative analysis confirmed the positive visual findings in 15O-water PET and the negative findings in 99mTc-HMPAO SPECT. Conclusion:15O-water PET enables detection of impaired CVRC in a considerable fraction of symptomatic patients with stenoocclusion and negative 99mTc-HMPAO SPECT.
AB - Cerebrovascular reserve capacity (CVRC) is an important parameter for treatment decisions in chronic cerebrovascular diseases. It can be assessed by measuring the acetazolamide-induced change in regional cerebral blood flow using SPECT with 99mTc-labeled hexamethylpropyleneamine oxime (99mTc-HMPAO) or PET with 15O-water. Methods: Our database was searched for patients with moyamoya vasculopathy or atherosclerotic cerebrovascular disease who had undergone 15O-water PET after normal 99mTc-HMPAO SPECT results with respect to CVRC. 15O-water PET was analyzed visually and quantitatively. Quantitative analysis was based on parametric CVRC maps generated by voxelwise image subtraction. Results: The search identified 18 patients (43 ± 15 y, 12 moyamoya vasculopathy). PET revealed impaired CVRC in 8 patients (44%). Quantitative analysis confirmed the positive visual findings in 15O-water PET and the negative findings in 99mTc-HMPAO SPECT. Conclusion:15O-water PET enables detection of impaired CVRC in a considerable fraction of symptomatic patients with stenoocclusion and negative 99mTc-HMPAO SPECT.
KW - Journal Article
UR - http://europepmc.org/abstract/med/28729429
U2 - 10.2967/jnumed.117.195818
DO - 10.2967/jnumed.117.195818
M3 - SCORING: Journal article
C2 - 28729429
VL - 59
SP - 294
EP - 298
JO - J NUCL MED
JF - J NUCL MED
SN - 0161-5505
IS - 2
ER -